May 18, 2020 / 11:44 AM / 11 days ago

BRIEF-Biogen Says New Spinraza Data Reinforce Sustained Efficacy And Longer-Term Safety Across Broad Range Of SMA Patients

May 18 (Reuters) - Biogen Inc:

* NEW SPINRAZA® (NUSINERSEN) DATA REINFORCE SUSTAINED EFFICACY AND LONGER-TERM SAFETY ACROSS BROAD RANGE OF SPINAL MUSCULAR ATROPHY (SMA) PATIENTS

* BIOGEN INC - TREATMENT WITH SPINRAZA IMPROVED OR STABILIZED MOTOR FUNCTION ACROSS PATIENT POPULATIONS, INCLUDING YOUNG ADULTS

* BIOGEN INC - LONGER-TERM SAFETY PROFILE OF SPINRAZA WAS CONSISTENT AMONG A BROAD SPECTRUM OF AGES AND SMA TYPES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below